Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Naji Maaliki"'
Autor:
Francesco Franchi, MD, Fabiana Rollini, MD, Victor Kairouz, MD, Jose Rivas Rios, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Maryuri Briceno, MD, Mustafa Wali, MD, Ahmed Nawaz, MD, Gabriel Silva, MD, Zubair Shaikh, MD, Naji Maaliki, MD, Latonya Been, AAS, Jason Piraino, DPM, Andres M. Pineda, MD, Siva Suryadevara, MD, Daniel Soffer, MD, Martin M. Zenni, MD, Lisa K. Jennings, PhD, Theodore A. Bass, MD, Dominick J. Angiolillo, MD, PhD
Publikováno v:
JACC: Basic to Translational Science, Vol 4, Iss 7, Pp 763-775 (2019)
Summary: Vorapaxar reduces thrombotic cardiovascular events at the expense of increased bleeding. However, the differential pharmacodynamic (PD) effects of vorapaxar according to diabetes mellitus (DM) status are unknown. Moreover, although withdrawa
Externí odkaz:
https://doaj.org/article/b7ea15f9ac70419180a5ce0ec8e4c853
Publikováno v:
IDCases, Vol 24, Iss , Pp e01149- (2021)
An 80-year-old patient was admitted for fever, chills, and chest wall pain. He had a past medical history significant for heart failure with a cardiac resynchronization therapy pacemaker implantation. Extensive workup revealed Enterobacter cloacae en
Externí odkaz:
https://doaj.org/article/b5c6335c3d64431fae74babbeac5b095
Publikováno v:
Case Reports in Cardiology, Vol 2021 (2021)
A 50-year-old male presented for loss of consciousness. He was initially treated with intravenous epinephrine and fluids, and an electrocardiogram (ECG) displayed an ST-segment elevation in lead aVR with global ST-segment depressions. A subsequent le
Externí odkaz:
https://doaj.org/article/051b99cb3b6f491da30fe81c38a40262
Autor:
Francesco Franchi, Fabiana Rollini, Gabriel Faz, Jose Ramon Rivas, Andrea Rivas, Malhar Agarwal, Maryuri Briceno, Mustafa Wali, Ahmed Nawaz, Gabriel Silva, Zubair Shaikh, Naji Maaliki, Kerolos Fahmi, Latonya Been, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Usman Baber, Roxana Mehran, Lisa K. Jennings, Theodore A. Bass, Dominick J. Angiolillo
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 8 (2020)
Background Vorapaxar as an adjunct to dual antiplatelet therapy (DAPT) reduces thrombotic events in patients with prior myocardial infarction at the expense of increased bleeding. Withdrawal of aspirin has emerged as a bleeding reduction strategy. Th
Externí odkaz:
https://doaj.org/article/febf58ad375f48bcb33144fe435a90c7
Publikováno v:
J Cardiol Cases
A 68-year-old woman with a past medical history of chronic obstructive pulmonary disease and squamous cell carcinoma of the lung with recent right upper and middle lobectomy was admitted for dyspnea and volume overload. She was diagnosed with right-s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::183165bf370b5d82c36e1c78d3810655
https://doi.org/10.1016/j.jccase.2021.06.007
https://doi.org/10.1016/j.jccase.2021.06.007
Autor:
Francesco, Franchi, Luis, Ortega-Paz, Fabiana, Rollini, Latonya, Been, Andrea, Rivas, Naji, Maaliki, Xuan, Zhou, Andres M, Pineda, Siva, Suryadevara, Daniel, Soffer, Martin, Zenni, Dominick J, Angiolillo
Publikováno v:
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
The impact of intense low-density lipoprotein cholesterol (LDL-C) reduction using a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor on profiles of platelet reactivity has yet to be explored.Our aim was to investigate the effects of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::33c8e383169b42c468c7b81cdd3617c3
https://pubmed.ncbi.nlm.nih.gov/36602868
https://pubmed.ncbi.nlm.nih.gov/36602868
Autor:
Azeem Rathore, Naji Maaliki, Pedro Adrover Lopez, Ele Wu, Madeline Mahowald, John Catanzaro, Stephen G. Keim, Prakash Suryanarayana
Publikováno v:
Heart Rhythm. 20:S543
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0b169647cdcf0a6a44551a921b5edb8
https://doi.org/10.1016/j.hrthm.2023.03.1161
https://doi.org/10.1016/j.hrthm.2023.03.1161
Autor:
Mattia Galli, Francesco Franchi, Fabiana Rollini, Latonya Been, Patrick Abou Jaoude, Andrea Rivas, Xuan Zhou, Sida Jia, Naji Maaliki, Chang Hoon Lee, Andres M Pineda, Siva Suryadevara, Daniel Soffer, Martin M Zenni, Tobias Geisler, Lisa K Jennings, Theodore A Bass, Dominick J Angiolillo
Publikováno v:
European heart journal. Cardiovascular pharmacotherapy. 8(7)
Aims Dual pathway inhibition (DPI) by adding a vascular dose of rivaroxaban to a single antiplatelet agent has emerged as a promising antithrombotic strategy. However, in most studies the antiplatelet agent of choice used in adjunct to a vascular dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cd7f29531b194772f31f99affe35102
https://pubmed.ncbi.nlm.nih.gov/35353154
https://pubmed.ncbi.nlm.nih.gov/35353154
Autor:
Mattia Galli, Francesco Franchi, Fabiana Rollini, Latonya Been, Patrick Abou Jaoude, Andrea Rivas, Xuan Zhou, Sida Jia, Naji Maaliki, Chang Hoon Lee, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Tobias Geisler, Lisa K. Jennings, Theodore A. Bass, Dominick J. Angiolillo
Publikováno v:
Thrombosis and haemostasis. 122(8)
Aim Inhibition of thrombin-mediated signaling processes using a vascular dose of rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI), reduces atherothrombotic events in patients with stable atherosclerotic disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2e8db2c8371a8f8f2057ff6b192adfa
https://pubmed.ncbi.nlm.nih.gov/34983074
https://pubmed.ncbi.nlm.nih.gov/34983074
Autor:
Mattia Galli, Francesco Franchi, Fabiana Rollini, Latonya Been, Patrick Jaoude, Andrea Rivas, Xuan Zhou, Sida Jia, Naji Maaliki, Chang Lee, Andres Pineda, Siva Suryadevara, Daniel Soffer, Martin Zenni, Lisa Jennings, Theodore Bass, Dominick J Angiolillo
Publikováno v:
European Heart Journal Supplements. 23
Aims Inhibition of thrombin-mediated signalling processes using a vascular dose of rivaroxaban in adjunct to single antiplatelet therapy, known as dual-pathway inhibition (DPI), reduces atherothrombotic events in patients with stable atherosclerotic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7215162bc93eba925ecf63e93f5b836
https://doi.org/10.1093/eurheartj/suab129.004
https://doi.org/10.1093/eurheartj/suab129.004